Matches in Nanopublications for { ?s ?p "[Crizotinib (XALKORI?, Pfizer) is a tyrosine kinase inhibitor targeting ALK, MET and ROS1, currently approved for the treatment of adults with ALK-rearranged non-small-cell lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- assertion description "[Crizotinib (XALKORI?, Pfizer) is a tyrosine kinase inhibitor targeting ALK, MET and ROS1, currently approved for the treatment of adults with ALK-rearranged non-small-cell lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Crizotinib (XALKORI?, Pfizer) is a tyrosine kinase inhibitor targeting ALK, MET and ROS1, currently approved for the treatment of adults with ALK-rearranged non-small-cell lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Crizotinib (XALKORI?, Pfizer) is a tyrosine kinase inhibitor targeting ALK, MET and ROS1, currently approved for the treatment of adults with ALK-rearranged non-small-cell lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1238970.RAuYewsbRlesdkjYemkndcgvYIQwLD1EWhzjZGBgkrYWY130_assertion description "[Crizotinib (XALKORI?, Pfizer) is a tyrosine kinase inhibitor targeting ALK, MET and ROS1, currently approved for the treatment of adults with ALK-rearranged non-small-cell lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1238970.RAuYewsbRlesdkjYemkndcgvYIQwLD1EWhzjZGBgkrYWY130_provenance.
- NP1238972.RAKhT-cq4iPJtnInsJtD5lzgbkCR06tnaTR59nwM3bCyY130_assertion description "[Crizotinib (XALKORI?, Pfizer) is a tyrosine kinase inhibitor targeting ALK, MET and ROS1, currently approved for the treatment of adults with ALK-rearranged non-small-cell lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1238972.RAKhT-cq4iPJtnInsJtD5lzgbkCR06tnaTR59nwM3bCyY130_provenance.
- NP1238971.RAydFsFXrjw4fjB8q97B3RN4Z8B8kIXvqYa8e8QsFRD7w130_assertion description "[Crizotinib (XALKORI?, Pfizer) is a tyrosine kinase inhibitor targeting ALK, MET and ROS1, currently approved for the treatment of adults with ALK-rearranged non-small-cell lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1238971.RAydFsFXrjw4fjB8q97B3RN4Z8B8kIXvqYa8e8QsFRD7w130_provenance.
- NP1238973.RAzjFxZKo1biQLweGcHIr-H35opqEmyIEPWn0fkAMhwlo130_assertion description "[Crizotinib (XALKORI?, Pfizer) is a tyrosine kinase inhibitor targeting ALK, MET and ROS1, currently approved for the treatment of adults with ALK-rearranged non-small-cell lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1238973.RAzjFxZKo1biQLweGcHIr-H35opqEmyIEPWn0fkAMhwlo130_provenance.